Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[30/03/2018]

UCB : UCB Media Room: Transparency Notification The Capital Group Companies Inc.

Transparency notification The Capital Group Companies Inc.Brussels Belgium, 30 March 2018 – 20:00 CEST – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 29 March 2018 from The Capital Group Companies, Inc. having its registered... See more
 
UCB [BE0003739530/UCB]   
[30/03/2018]

UCB : UCB Media Room: Cimzia Filing Acceptance China

UCB Announces Filing Acceptance with the China Food and Drug Administration for CIMZIA® certolizumab pegol for the Treatment of ModeratetoSevere Rheumatoid ArthritisBrussels, Belgium – 30 March, 7:00 CEST – UCB, a global biopharmaceutical company, today announced the submission of an application for an Import Drug License to the Chinese Food and Drug Administration CFDA for the approval of... See more
 
UCB [BE0003739530/UCB]   
[22/03/2018]

UCB : UCB Media Room: Cimzia label update in the US

CIMZIA® certolizumab pegol label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.U.S. Food and Drug Administration FDA approves label change for UCB’s CIMZIA® certolizumab pegolData added to the label includes firstoftheirkind pharmacokinetic studies demonstrating negligible to low transfer of CIMZIA through placenta and minimal transfer... See more
 
UCB [BE0003739530/UCB]   
[22/02/2018]

UCB : UCB Media Room: Full Year Results

UCB Full Year Report 2017:UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growthBrussels Belgium, 22 February 2018 – 7:00 CET – regulated information – UCB Full Year Report 2017:Positive growth momentum of core products drive top and bottom line growthProfitability surpasses 30% rEBITDA margin – one year ahead of guidanceR&D update: positive Phase... See more
 
UCB [BE0003739530/UCB]   
[16/02/2018]

UCB : UCB Media Room: American Academy of Dermatology

UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting AAD 2018Oral presentation of Phase 2b findings for bimekizumab in the treatment of moderatetosevere chronic plaque psoriasis patients will focus on the effects of dual neutralization of both IL17A and IL17FThree pooled subanalyses from ongoing, Phase 3 studies CIMPASI1, CIMPASI2 and CIMPACT... See more